Emilie Yab

Aug 21, 2024 | biorxiv.org | Delphine Planas |Isabelle Staropoli |Cyril Planchais |Emilie Yab

AbstractFirst-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, two novel mAbs, Pemivibart and Sipavibart, have been approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.